Skip to main content
Skye Bioscience, Inc. logo

Skye Bioscience, Inc. — Investor Relations & Filings

Ticker · SKYE ISIN · US83086J2006 LEI · 5493004823BTPRPZ8750 US Professional, scientific and technical activities
Open in API
Filings indexed 587 across all filing types
Latest filing 2026-05-29 Declaration of Voting R…
Country US United States of America
Listing US SKYE

About Skye Bioscience, Inc.

https://skyebioscience.com/

Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on developing treatments for obesity and other metabolic diseases. The company's strategy involves advancing first-in-class molecules that modulate G-protein coupled receptors (GPCRs). Its lead drug candidate, nimacimab, is a peripherally-acting antibody that inhibits the cannabinoid receptor 1 (CB1). Nimacimab is designed to target CB1 receptors in peripheral tissues like adipose, liver, and muscle, with the goal of reducing hunger and increasing energy expenditure while limiting central nervous system exposure. This mechanism is being investigated for its potential as a complementary approach to existing obesity therapies, aiming to provide more sustainable weight loss, improved body composition, and better tolerability. Nimacimab is being evaluated in Phase 2 clinical trials.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a Form 8-K current report under the Exchange Act primarily detailing the outcomes of shareholder votes at the company’s 2026 Annual Meeting (election of directors, ratification of auditor, approval of charter amendment, advisory vote on compensation) and providing vote tallies. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement.
2026-05-29 English
8-K
Delisting Announcement Classification · 92% confidence The document is a Form 8-K current report filed under Item 3.01 “Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard.” It notifies investors that Nasdaq has informed the company it is out of compliance with the minimum stockholders’ equity requirement and describes potential delisting procedures. This matches the definition of a Delisting Announcement (DLST).
2026-05-15 English
ARS - Skye Bioscience, Inc. (0001516551) (Filer)
Annual Report
2026-04-16 English
DEF 14A - Skye Bioscience, Inc. (0001516551) (Filer)
Proxy Solicitation & Information Statement
2026-04-16 English
8-K - Skye Bioscience, Inc. (0001516551) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes an announcement of a stock option repricing and the appointment of a new Chief Financial Officer, along with details about a Master Services Agreement. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The document primarily announces changes in senior management and compensatory arrangements, which aligns with the category for Board/Management Information (MANG). The document length is 8290 characters, which is sufficient for a detailed announcement but does not constitute a full financial report. Therefore, the appropriate classification is MANG with high confidence.
2026-04-03 English
8-K - Skye Bioscience, Inc. (0001516551) (Filer)
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The key content is a notice from Nasdaq about the company's stock price falling below the minimum bid price required for continued listing, and the potential consequences including delisting if compliance is not regained. The document specifically includes a section titled 'Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.' This clearly indicates it is an official notice regarding potential delisting. The document is about 4907 characters, which is relatively short and focused on this specific event, not a full financial report or earnings release. Therefore, the appropriate classification is a Delisting Announcement (DLST).
2026-03-19 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.